🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for Locally Advanced Differentiated Thyroid Gland Carcinoma

Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer NCT06431620NA1 site📍 Nanjing Nanjing First Hospital, Nanjing Medical University · Tests: Recombinant Human Thyroid Stimulating Hormone Adjuvant Radiotherapy in High Risk Locally Advanced DTC NCT06558981Phase 31 site📍 Shanghai Fudan University · Tests: Radiotherapy, radioiodine treatment Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer NCT06970353Phase 21 site📍 Shanghai Fudan University · Tests: Tunlametinib, Tunlametinib+PD-1 mAb Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer NCT06359847Phase 21 site📍 Beijing Beijing Scitech-Mq Pharmaceuticals Limited · Tests: ST-1898 tablets XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer NCT06959641Phase 22 sites📍 Torrance📍 Chicago Jochen Lorch · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment NCT06405217NA1 site📍 Nanjing Nanjing First Hospital, Nanjing Medical University · Tests: Recombinant Human Thyroid Stimulating Hormone Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma NCT05994365n/a3 sites📍 Beijing📍 Tianjin📍 Tianjin Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: Anlotinib Hydrochloride Capsule A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma NCT06860971Phase 335 sites📍 Hefei📍 Beijing📍 Chongqing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: AL2846 Capsules, AL2846 Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy